Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on: December 22,2023

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on:December 22,2023

Cardiopulmonary fitness is key for helping breast cancer patients manage post-diagnosis symptoms, say researchers

by Adrianna MacPherson,University of AlbertaIndependent associations between health-related fitness variables and breast cancer-related symptoms in newly diagnosed breast cancer patients. (A) Mo

Updated on: October 26,2024

Cardiopulmonary fitness is key for helping breast cancer patients manage post-diagnosis symptoms, say researchers

by Adrianna MacPherson,University of AlbertaIndependent associations between health-related fitness variables and breast cancer-related symptoms in newly diagnosed breast cancer patients. (A) Mo

Updated on:October 26,2024

Survivors of childhood cancers at risk for shortened life span

(HealthDay)—Survivors of childhood cancer remain at risk for shorter life spans, especially when they receive radiotherapy, according to a study published online Jan. 2 inJAMA Oncology.Jennifer

Updated on: December 20,2023

Survivors of childhood cancers at risk for shortened life span

(HealthDay)—Survivors of childhood cancer remain at risk for shorter life spans, especially when they receive radiotherapy, according to a study published online Jan. 2 inJAMA Oncology.Jennifer

Updated on:December 20,2023

Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial

byMayo ClinicCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenanc

Updated on: December 22,2023

Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial

byMayo ClinicCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenanc

Updated on:December 22,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on: October 24,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on:October 24,2023

Advanced imaging may help in clinical treatment of prostate cancer

byEuropean Association of UrologyCredit: Pixabay/CC0 Public DomainAn advanced imaging method is showing promise as a way to improve the diagnosis of prostate cancer by giving clinicians a cleare

Updated on: January 10,2024

Advanced imaging may help in clinical treatment of prostate cancer

byEuropean Association of UrologyCredit: Pixabay/CC0 Public DomainAn advanced imaging method is showing promise as a way to improve the diagnosis of prostate cancer by giving clinicians a cleare

Updated on:January 10,2024

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML

August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse

Updated on: October 12,2023

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML

August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse

Updated on:October 12,2023

Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

byWolters Kluwer HealthCredit: Pixabay/CC0 Public DomainNipple-sparing mastectomy (NSM)—an increasingly popular option for women undergoing treatment for breast cancer—not only achieves good cos

Updated on: December 19,2023

Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

byWolters Kluwer HealthCredit: Pixabay/CC0 Public DomainNipple-sparing mastectomy (NSM)—an increasingly popular option for women undergoing treatment for breast cancer—not only achieves good cos

Updated on:December 19,2023

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on: October 12,2023

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on:October 12,2023

New study reveals how blood cancer cells escape the immune system's natural killer cells

byUniversity of HelsinkiGraphical abstract. Credit:Immunity(2023). DOI: 10.1016/j.immuni.2023.11.008The advent of T-cell therapies, where cells of the immune system are directed towa

Updated on: January 26,2024

New study reveals how blood cancer cells escape the immune system's natural killer cells

byUniversity of HelsinkiGraphical abstract. Credit:Immunity(2023). DOI: 10.1016/j.immuni.2023.11.008The advent of T-cell therapies, where cells of the immune system are directed towa

Updated on:January 26,2024

Exploring key regulators of programmed cell death in melanoma and the immune system's response

byBrigham and Women’s HospitalExpression of type I interferon receptors by melanoma cells. Credit:Nature Communications(2024). DOI: 10.1038/s41467-024-51496-2A new paperpublish

Updated on: September 10,2024

Exploring key regulators of programmed cell death in melanoma and the immune system's response

byBrigham and Women’s HospitalExpression of type I interferon receptors by melanoma cells. Credit:Nature Communications(2024). DOI: 10.1038/s41467-024-51496-2A new paperpublish

Updated on:September 10,2024

Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on: December 21,2023

Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on:December 21,2023